|| Checking for direct PDF access through Ovid
In 16 prospectively treated patients with human immunodeficiency virus–associated pulmonary hypertension, use of bosentan improved 6-minute walk distances, cardiopulmonary hemodynamics, New York Heart Association functional class, and quality-of-life measures. In addition, there appeared to be no untoward side effects or drug interactions.Sitbon O et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212–1217.